SNY - Pharma Giants Sanofi Johnson & Johnson Join Forces To Develop E.coli Vaccine | Benzinga
Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent).
The vaccine is currently in Phase 3 E.mbrace trial designed to evaluate the efficacy of the 9-valent extraintestinal pathogenic E. coli vaccine (ExPEC9V) compared to placebo in the prevention ...